Testing effectiveness (Phase 2)Study completedNCT03192202What this trial is testingAFM13 in Relapsed/Refractory Cutaneous LymphomasWho this might be right forLymphoma, T-Cell, Cutaneous Ahmed Sawas 18
Testing effectiveness (Phase 2)Study completedNCT00003737What this trial is testingRebeccamycin Analog in Treating Children With Relapsed or Refractory NeuroblastomaWho this might be right forNeuroblastoma Memorial Sloan Kettering Cancer Center 30
Early research (Phase 1)UnknownNCT04004637What this trial is testingCD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic LeukemiaWho this might be right forT-lymphoblastic LymphomaNK/T Cell LymphomaAcute Lymphocytic Leukemia PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)UnknownNCT06027853What this trial is testingNatural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid LeukemiaWho this might be right forAML, Adult Zhejiang University 24
Testing effectiveness (Phase 2)Study completedNCT07102706What this trial is testingPhase I Trial of GR1803 Injection in Patients With RRMMWho this might be right forMultiple Myeloma (MM) Genrix (Shanghai) Biopharmaceutical Co., Ltd. 76
Testing effectiveness (Phase 2)UnknownNCT05381506What this trial is testingStudy of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell LymphomaWho this might be right forDLBCL Sun Yat-sen University 77
Early research (Phase 1)Active Not RecruitingNCT05784441What this trial is testingJNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)Who this might be right forRelapsed or Refractory B Cell Non-Hodgkin Lymphoma Janssen Research & Development, LLC 21
Very early researchUnknownNCT05180851What this trial is testingSafety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical StudyWho this might be right forHead and Neck CancerMelanomaBreast Cancer+4 more Shanghai Fengxian District Central Hospital 28
Testing effectiveness (Phase 2)Study completedNCT01244451What this trial is testingGIMEMA CLL0809 Study (BendOfa)Who this might be right forPatients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; orPatients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines Gruppo Italiano Malattie EMatologiche dell'Adulto 49
Testing effectiveness (Phase 2)Looking for participantsNCT07306156What this trial is testingGP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid NeoplasmsWho this might be right forEBV Associated Lymphoid Neoplasms Zhimin Zhai 24
Early research (Phase 1)Study completedNCT01246622What this trial is testingLenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWho this might be right forAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+4 more Roswell Park Cancer Institute 32
Testing effectiveness (Phase 2)UnknownNCT02248402What this trial is testingAutologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Chonnam National University Hospital 15
Testing effectiveness (Phase 2)UnknownNCT05137886What this trial is testingPD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's LymphomaWho this might be right forHodgkin Lymphoma, AdultRelapseRefractory Hodgkin Lymphoma Institute of Hematology & Blood Diseases Hospital, China 47
Testing effectiveness (Phase 2)Study completedNCT05844956What this trial is testingDZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)Who this might be right forLymphoma, Non-Hodgkin Dizal Pharmaceuticals 17
Testing effectiveness (Phase 2)Study completedNCT00422656What this trial is testingPerifosine in Patients With Relapsed/Refractory Waldenstrom's MacroglobulinemiaWho this might be right forWaldenstrom's Macroglobulinemia Dana-Farber Cancer Institute 37
Early research (Phase 1)WithdrawnNCT02875002What this trial is testingStudy of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell LymphomasWho this might be right forRelapsed and Refractory Aggressive B- and T-cell LymphomasLymphoma Yale University
Testing effectiveness (Phase 2)UnknownNCT01216839What this trial is testingPhase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue SarcomasWho this might be right forRefractory or Relapsed RMS and Soft Tissue Sarcomas Sidnei Epelman 20
Post-approval studies (Phase 4)WithdrawnNCT05183139What this trial is testingIn-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Takeda
Testing effectiveness (Phase 2)Study completedNCT01082939What this trial is testingCyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Who this might be right forChronic Lymphocytic Leukemia M.D. Anderson Cancer Center 80
Early research (Phase 1)Study completedNCT03125239What this trial is testingCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaWho this might be right forRelapsed Adult Acute Myeloid LeukemiaRefractory Adult Acute Myeloid Leukemia Jacqueline Garcia, MD 16